Skip to content
    Guidelines & Consensus

    Projected Health Expenditures of Precision Medicine Under a Value-Based Pricing Framework

    GandjourOperations Research Forum

    A mathematical modeling study evaluated the budgetary implications of integrating precision medicine (PM) into a value-based pricing framework, calibrated using market dynamics and drug pricing data from the German social health insurance system. The model incorporated three distinct cost drivers: optimization of therapeutic selection via novel biomarkers to curb spending on ineffective interventions, the adoption and utilization of premium-priced targeted therapeutics, and upfront spending dedicated to early detection and diagnostic screening.
    The base-case analysis revealed that the transition to precision medicine is not inherently cost-neutral. Over a 10- to 20-year projection window, PM is estimated to generate a net increase in annual expenditures of approximately €2.6 billion. Although the implementation of predictive and targeted biomarkers reduces the financial waste associated with ineffective standard treatments, these cost offsets are completely counterbalanced by the high upfront expenses of advanced diagnostics and the sustained costs of novel targeted pharmaceuticals.
    Extensive sensitivity analyses demonstrated substantial budgetary uncertainty, underscoring that long-term fiscal sustainability hinges on real-world therapeutic efficacy, competitive dynamics among pharmaceutical and diagnostic manufacturers, and disciplined pricing mechanisms. Overall economic projections diverged widely across model configurations, presenting an optimal scenario of €1.6 billion in annual net savings contrasted against an adverse scenario projecting an annual PM-related expenditure escalation of up to €34.7 billion.

    Key Takeaways

    • Under base-case assumptions within the German social health insurance system, transitioning to precision medicine is projected to increase annual healthcare expenditures by approximately €2.6 billion over a 10- to 20-year horizon.
    • Sensitivity analyses demonstrate wide financial variability based on market dynamics, efficacy, and pricing frameworks, ranging from €1.6 billion in net annual savings in an optimal scenario to an annual expenditure surge of €34.7 billion in an adverse scenario.
    Read the original sourceOperations Research Forum